Biohaven announced positive topline results from a pivotal phase 2/3 study evaluating rimegepant for the preventive treatment of episodic and chronic migraine in adults.
This week we talk about the ban on certain electrical stimulation devices, the latest COVID-19 news, a first generic of Daraprim, a New Drug Application for a potential microneedle migraine treatment patch, and a first over-the-counter combination of ibuprofen and acetaminophen.
Investigators sought to determine the long-term safety and efficacy of fremanezumab in patients with chronic migraine and comorbid moderate to severe depression.
This slideshow reviews drug information for Ajovy. Click here for the complete Ajovy new product monograph. For a downloadable PDF of this slideshow, click here.
The primary efficacy endpoint was the mean change from baseline in the monthly average number of headache days of at least moderate severity during the 3-month treatment period.
The label includes a Boxed Warning describing the risk of hepatotoxicity associated with APAP. Most cases of liver injury were associated with APAP doses >4000mg daily and often involved >1 APAP-containing product.
The efficacy of Aimovig was evaluated as a preventive treatment of episodic or chronic migraine in 3 randomized, double-blind, placebo-controlled studies: 2 studies in patients with episodic migraine (4-14 migraine days per month) and 1 study in patients with chronic migraine (≥15 headache days per month with ≥8 migraine days per month).
DFN-02 was evaluated in a multicenter, double-blind, randomized, placebo-controlled study (N=107) which showed it was effective in treating pain and associated symptoms during a migraine attack and in reducing attack-related functional disability.
Both strengths of Sumavel DosePro have now been discontinued.
Aimovig is a fully human monoclonal antibody, designed to selectively block the calcitonin gene-related peptide (CGRP) receptor.
